Methods for treating spinal cord injury with a compound that inhibits a NCCA-ATP channel
AssigneesThe United States of America as represented by the Department of Veteran Affairs, University of Maryland, Baltimore
InventorJ. Marc Simard
Life of this patent
Estimating the term…
Abstract
The present invention is directed to therapeutic compositions targeting the NCCa-ATP channel of an astrocyte, neuron or capillary endothelial cell and methods of using same. More specifically, antagonists of the NCCa-ATP channel are contemplated. The compositions are used to prevent cell death and to treat secondary damage associated with spinal cord injury.
Claims9
A method of treating a subject at risk for developing a spinal cord injury comprising administering to the subject a compound effective to inhibit a NCCa-ATP channel in a neuronal cell, a neuroglia cell, a neural endothelial cell or a combination thereof, wherein the compound is glibenclamide, and
- wherein the subject is undergoing a surgical treatment or radiation treatment.
Dependencies are inferred from the claim text.